Skip to Content
Merck
  • 1B50-1, a mAb raised against recurrent tumor cells, targets liver tumor-initiating cells by binding to the calcium channel α2δ1 subunit.

1B50-1, a mAb raised against recurrent tumor cells, targets liver tumor-initiating cells by binding to the calcium channel α2δ1 subunit.

Cancer cell (2013-04-20)
Wei Zhao, Limin Wang, Haibo Han, Kemin Jin, Na Lin, Ting Guo, Yangde Chen, Heping Cheng, Fengmin Lu, Weigang Fang, Yu Wang, Baocai Xing, Zhiqian Zhang
ABSTRACT

The identification and targeted therapy of cells involved in hepatocellular carcinoma (HCC) recurrence remain challenging. Here, we generated a monoclonal antibody against recurrent HCC, 1B50-1, that bound the isoform 5 of the α2δ1 subunit of voltage-gated calcium channels and identified a subset of tumor-initiating cells (TICs) with stem cell-like properties. A surgical margin with cells detected by 1B50-1 predicted rapid recurrence. Furthermore, 1B50-1 had a therapeutic effect on HCC engraftments by eliminating TICs. Finally, α2δ1 knockdown reduced self-renewal and tumor formation capacities and induced apoptosis of TICs, whereas its overexpression led to enhanced sphere formation, which is regulated by calcium influx. Thus, α2δ1 is a functional liver TIC marker, and its inhibitors may serve as potential anti-HCC drugs.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-CACNA2D1 antibody produced in rabbit, affinity isolated antibody, buffered aqueous glycerol solution
SKU
Pack Size
Availability
Price
Quantity